NeuroBo Pharmaceuticals (NRBO)
(Delayed Data from NSDQ)
$2.56 USD
+0.09 (3.64%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $2.56 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.56 USD
+0.09 (3.64%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $2.56 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals
by Zacks Equity Research
Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals are part of the Zacks top Analyst Blog.
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
by Indrajit Bandyopadhyay
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
Want to Shrug Off Volatility? Buy 3 Medical Growth Stocks
by Indrajit Bandyopadhyay
We pick three medical stocks - MOH, RDY and NRBO - that have gained more than 5% in the past three months amid market volatility.
Here's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
NeuroBo Pharmaceuticals, Inc. (NRBO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
NeuroBo Pharmaceuticals (NRBO) Surges: Stock Moves 5.2% Higher
by Zacks Equity Research
NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
New Strong Buy Stocks For May 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
SunOpta Up 35.6%, What To Do Now?
by Sejuti Banerjea
Is it time to cash out of SunOpta?
New Strong Buy Stocks For May 27th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks For April 22nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: